Here, we presented new clinical evidence that TPD52L2 had no correlation with the prognosis of patients with luminal A and luminal B breast cancers and failed to predict the clinical outcomes of lymph node-positive patients with luminal subtype breast cancers (Figures 2(a) and 2(b)). This evidence concerns the gene TPD52L2 and breast cancer.